MD MBA - Assertio Therapeutics Senior Medical

Assertio Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4236) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.8 in 2024. Return On Capital Employed is likely to gain to -1.2 in 2024. Liabilities And Stockholders Equity is likely to gain to about 336.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 72.3 M in 2024.

Similar Executives

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Assertio Therapeutics (ASRT) is traded on NASDAQ Exchange in USA. It is located in 100 South Saunders Road, Lake Forest, IL, United States, 60045 and employs 53 people. Assertio Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Assertio Therapeutics Leadership Team

Assertio Stock Performance Indicators

Additional Tools for Assertio Stock Analysis